FBLG 8-K
FibroBiologics, Inc. (FBLG)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 20, 2026, the Board of Directors (the “Board”) of FibroBiologics, Inc. (the “Company”) appointed Leigh Steinberg as a Class II director of the Board, effective August 20, 2026, to serve until the expiration of his term at the 2028 annual meeting of stockholders.
In connection with his appointment, Mr. Steinberg will be entitled to receive compensation consistent with that of the Company’s other non-employee directors under the Company’s Non-Employee Director Compensation Policy, as such policy may be amended from time to time.
Mr. Steinberg is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K, and there are no arrangements or understandings between Mr. Steinberg and any other persons pursuant to which he was selected as a director.
The Company also entered into its standard form of indemnification agreement with Mr. Steinberg, which will require the Company to indemnify Mr. Steinberg against certain liabilities that may arise as a result of his status or service as a director of the Company. The description of the Company’s standard form of indemnification agreement is qualified in its entirety by reference to the full text of the form of indemnification agreement, a copy of which is filed as Exhibit 10.19 to the Company’s Annual Report on Form 10-K filed with the SEC on February 24, 2026.
Item 7.01 Regulation FD Disclosure.
A copy of the Company’s press release announcing the appointment of Mr. Steinberg to the Board has been furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01.
The information in this report furnished pursuant to Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this report.
Item 9.01 Financial Statements and Exhibits.
|
||
Exhibit 104 |
|
Cover Page Interactive Data File (embedded within the inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
FibroBiologics, Inc. |
|
|
|
|
Date: |
August 24, 2026 |
By: |
/s/ Pete O'Heeron |
|
|
|
Name: Pete O'Heeron |
Exhibit 99.1
FibroBiologics Appoints Leigh Steinberg to Board of Directors
Legendary Sports Agent, Attorney, and Longtime Advocate for Human Longevity and Brain Health Joins Board
HOUSTON, August 24, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the appointment of Leigh Steinberg to its Board of Directors. Widely regarded as the most influential sports agent of his generation, Mr. Steinberg brings five decades of dealmaking experience, a deep commitment to human longevity research, and a long record of initiatives in chronic disease awareness and management.
Pete O'Heeron, Chief Executive Officer and Chairman of FibroBiologics, said, "Leigh has spent his career looking around corners. Long before brain health and longevity became national conversations, he was convening physicians and researchers to protect the long-term health of his athletes, and he has carried that same focus into chronic disease advocacy for decades. His negotiating skill is unmatched, and his circle of influence and contacts across sports, medicine, business, and media is simply unparalleled. As we advance our fibroblast-based pipeline, including our human longevity program, Leigh will be a powerful voice at our board table and a tremendous asset to our shareholders."
"I have spent much of my life asking how we help people live longer, healthier lives, from the brain health summits I began holding for my players in the 1990s to my ongoing work in longevity and chronic disease awareness," said Mr. Steinberg. "FibroBiologics is attacking chronic disease at its roots with fibroblast cell therapy, and the breadth of its science and patent portfolio is remarkable. I am honored to join the Board and to put my experience, my relationships, and my negotiating background to work for the company and the patients it aims to serve."
Mr. Steinberg is the Chief Executive Officer of Steinberg Sports & Entertainment. Over a career spanning more than 50 years, he has represented over 300 professional athletes across football, baseball, basketball, boxing, and Olympic sports, including a record eight No. 1 overall picks in the NFL Draft and more than 60 first-round selections. He has negotiated over $4 billion in contracts for his clients and directed more than $800 million to charities around the world, earning commendations from Congress, numerous cities and states, and Presidents Reagan, Bush, and Clinton. His career served as the inspiration for the Academy Award-winning film Jerry Maguire.
Beyond the negotiating table, Mr. Steinberg has been a pioneering advocate for long-term human health. Beginning in 1994, he organized annual brain health summits that brought leading neurologists together with athletes to address the risks of traumatic brain injury, work that helped bring concussion awareness
into the national spotlight. He recently launched the Leigh Steinberg Foundation to fund research and promote awareness, prevention, and treatment of neurological injury, and he is a passionate champion of health technologies that extend performance, manage pain, and enhance longevity. Mr. Steinberg is the best-selling author of Winning with Integrity, a guide to non-confrontational negotiation, and The Agent: My 40-Year Career of Making Deals and Changing the Game. He holds a B.A. in political science and a J.D. from the University of California, Berkeley.
For more information, please visit FibroBiologics' website, email FibroBiologics at [email protected] or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning plans for, and the anticipated timing of the initiation of and results from, FibroBiologics' clinical trials and research and development programs, and the potential clinical benefits of fibroblasts and fibroblast-derived materials. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics' R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; (d) the ability of FibroBiologics to successfully prosecute its patent applications, (e) FibroBiologics' ability to manufacture its product candidates; and (f) FibroBiologics' ability to conduct clinical trials. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
General Inquiries:
[email protected]
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
[email protected]
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
[email protected]